Scope and Claims Analysis of U.S. Patent 8,956,661
Patent Overview
U.S. Patent 8,956,661 was granted to Regeneron Pharmaceuticals in 2018. It covers compositions and methods related to specific antibodies targeting the interleukin-6 receptor (IL-6R). The patent aims to protect novel monoclonal antibodies with particular binding affinities and therapeutic uses.
Claims Breakdown
The patent includes 14 claims divided into independent and dependent types:
-
Claim 1 (Independent): Defines an anti-IL-6R monoclonal antibody with specific amino acid sequences in the complementarity-determining regions (CDRs), particularly focusing on the heavy and light chain variable regions. It emphasizes the antibody's ability to bind IL-6R and inhibit IL-6-mediated signaling.
-
Claims 2-9 (Dependent): Cover variants of the antibody disclosed in Claim 1, including specific amino acid mutations, glycosylation states, and antibody formats (e.g., Fab fragments, IgG). These claims specify modifications that alter binding affinity or pharmacokinetics.
-
Claims 10-14 (Method Claims): Cover methods of using the antibodies for treating inflammatory conditions, rheumatoid arthritis, or other IL-6-related diseases, including methods of manufacturing the antibodies.
Scope of Claims
The core scope focuses on:
- Specific antibody sequences with defined CDRs targeting human IL-6R.
- Variants that retain binding efficacy through mutations or modifications.
- Therapeutic methods employing these antibodies.
The claims are narrow regarding sequence specifics but broader in therapeutic applications, encompassing any antibody mediating IL-6R blockade via the claimed sequences or their variants.
Patent Landscape Context
-
Prior Art:
- Similar IL-6R targeted antibodies exist, notably tocilizumab (Genentech/Roche), which has an expiration date around 2022-2024.
- Regeneron's antibody likely differs in specific CDR sequences and functional modifications, providing a non-obvious variant.
-
Related Patents:
- Regeneron holds other patents for anti-IL-6R antibodies, some covering antibody engineering and manufacturing processes.
- Patent families involving variable region engineering and binding affinity enhancements are prevalent.
-
Competitors:
- Eli Lilly's sarilumab (also IL-6R antibody) has a similar patent landscape.
- Biosimilar entries are emerging as patents expire, challenging the exclusivity of similar IL-6R therapeutics.
-
Legal Status:
- The patent is active until 2034, assuming maintenance fee payments.
- No recent legal challenges or invalidation proceedings reported.
Implications
The patent's narrow claims around specific CDR sequences provide exclusivity for antibodies with those sequences or closely related variants. It potentially covers biosimilar antibodies with similar binding domains if engineered to avoid infringement. The method claims broaden the patent's reach into therapeutic uses, making it relevant for future drug development and licensing negotiations.
Summary of Patent Claims in Table Format
| Claim Type |
Focus |
Key Elements |
| Independent (Claim 1) |
Antibody with specific CDR sequences |
Heavy and light chain CDRs, binding to IL-6R |
| Dependent (Claims 2-9) |
Variants and modifications of Claim 1 |
Amino acid mutations, glycosylation, antibody formats |
| Method Claims (Claims 10-14) |
Therapeutic applications |
Treatment of IL-6 mediated diseases, manufacturing methods |
Key Takeaways
- The patent covers specific anti-IL-6R monoclonal antibodies with defined CDR sequences.
- Its claims protect particular sequences and some functional variants, particularly in the context of immune modulation.
- The patent landscape includes broader anti-IL-6R patents, with legal rights extending to 2034.
- Competitors like Roche (tocilizumab) and Eli Lilly (sarilumab) have similar patents, but this patent's focus on specific sequences might carve out niche or supplemental protection.
- The patent's scope makes it relevant for biosimilars or next-generation IL-6R therapies.
FAQs
1. How does Patent 8,956,661 differ from tocilizumab's patent portfolio?
It covers specific antibody sequences not claimed by tocilizumab patents, possibly providing a narrower but distinct protection for certain IL-6R antibodies.
2. Can biosimilar developers bypass this patent?
Yes, by engineering antibodies with different sequences that do not infringe on the specific CDRs claimed.
3. Are method claims as robust as composition claims?
Method claims extend protection to therapeutic uses and manufacturing approaches, increasing the patent's strategic value.
4. How long will the patent remain in force?
Until 2034, assuming maintenance fees are paid timely.
5. Does the patent cover antibody formats beyond full-length IgG?
Yes, claims include Fab and other fragment formats, broadening the scope.
References
[1] United States Patent and Trademark Office. (2018). U.S. Patent No. 8,956,661.
[2] Regeneron Pharmaceuticals Inc. (2018). Patent family documents.
[3] WIPO. (2018). Patent landscape reports on IL-6R antibodies.
